SuperworthBeOne Medicines profit margin ONC
Gross, operating and net profit as a share of revenue over the last twelve months, from 2017.
- Net margin, 12 months
- 10.7%
- Operating margin, 12 months
- 15.1%
- Net margin on a year earlier
- +14.6 pts
- Peer median
- 26.3%
Over the twelve months to Jun 30, 2026, BeOne Medicines kept 10.7% of its revenue as net profit, with an operating margin of 15.1% and a gross margin of 88.9%.
The median for 10 biotech stocks of a similar size is 26.3%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 5.4% | 8.4% | 87.5% |
| FY2024 | −16.9% | −14.9% | 84.4% |
| FY2023 | −35.9% | −49.1% | 84.5% |
| FY2022 | n/a | n/a | 79.8% |
| FY2021 | n/a | n/a | 86.0% |
| FY2020 | n/a | n/a | 77.1% |
| FY2019 | n/a | n/a | 83.4% |
| FY2018 | n/a | n/a | 85.5% |
| FY2017 | −39.1% | −41.3% | n/a |
| FY2016 | n/a | n/a | n/a |
| FY2015 | n/a | n/a | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 10.7% | +14.6 pts | 15.1% | |
| Q1 FY26 | 8.9% | +18.3 pts | 12.0% | |
| Q4 FY25 | 5.4% | +22.3 pts | 8.4% | |
| Q3 FY25 | 1.4% | +27.3 pts | 3.7% | |
| Q2 FY25 | −3.9% | +13.0 pts | −2.2% | |
| Q1 FY25 | −9.4% | +19.0 pts | −7.1% | |
| Q4 FY24 | −16.9% | +18.9 pts | −14.9% | |
| Q3 FY24 | −25.9% | +17.6 pts | −26.3% | |
| Q2 FY24 | −16.9% | +78.8 pts | −28.6% | |
| Q1 FY24 | −28.4% | n/a | −39.7% | |
| Q4 FY23 | −35.9% | n/a | −49.1% | |
| Q3 FY23 | −43.5% | n/a | −58.6% |
Against its peers
Companies in Biotechnology nearest BeOne Medicines' size, closest first, today.
| Company | Profit margin |
|---|---|
| ONCBeOne Medicines | 10.7% |
| ALNYAlnylam Pharmaceuticals | 16.8% |
| UTHRUnited Therapeutics | 41.6% |
| INCYIncyte | 27.7% |
| REGNRegeneron Pharmaceuticals | 27.9% |
| EXELExelixis | 35.3% |
| NBIXNeurocrine Biosciences | 20.9% |
| HALOHalozyme Therapeutics | 24.9% |
| VRTXVertex Pharmaceuticals | 35.0% |
| TECHBIO-TECHNE | 15.0% |
| RGENRepligen | 5.3% |
| Peer median | 26.3% |
Where BeOne Medicines ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on BeOne Medicines
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.